Univdatos Whatsapp
Hereditary Angioedema market

Improved Diagnosis of Hereditary Angioedema Due to Technological Advancements Resulting in Significant Market Growth. North America to Witness the Strong Growth.

Hereditary Angioedema market is expected to exceed the market valuation of more than ~US$ 5 billion by 2027 expanding at a reasonable CAGR of around ~9% during the forecast period (2021-2027). Approximately 93% of patients with hereditary angioedema (HAE) experience recurrent abdominal pain. Many of these patients present to emergency departments, primary care physicians, general surgeons, or gastroenterologists, are misdiagnosed for years and undergo unnecessary testing and surgical patients, who often present to emergency departments, primary care physicians, general surgeons, or gastroenterologists, are misdiagnosed for years and undergo unnecessary testing and surgical procedures. Making the diagnosis of HAE can be challenging because symptoms and attack locations are often inconsistent from one episode to the next. Some of the symptoms include unexplained abdominal pain, particularly when accompanied by swelling of the face and extremities, suggests the diagnosis of HAE. In addition, family history and radiologic imaging demonstrating edematous bowel also support an HAE diagnosis.

For a detailed analysis of the Hereditary Angioedema Market browse through https://univdatos.com/report/hereditary-angioedema-market-current-analysis-and-forecast-2021-2027-2/

Key reasons for the market growth is the rapidly growing prevalence of hereditary angioedema, rising demand for preventive care, increasing awareness of the disorder and others. According to the National Organization for Rare Disorders (NORD), around 1-9 people per 100,000 population are affected by the condition. The actual number of individuals with the condition is significantly higher due to under reporting and misdiagnosis. The major reason for the misdiagnosis of this disease is its lack of awareness, which in turn leads to inadequate treatment that’s provided to the patients. Most patients with hereditary angioedema are misdiagnosed for conditions related to appendicitis, gastrointestinal disorders and other non-allergic angioedema. Significant number of patients being misdiagnosed for the condition has generated a vast patient pool with substantial medical needs. This is likely to be a key driving factor for the market growth.

For a detailed analysis of the market drivers in Hereditary Angioedema Market browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=15857

At the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, age more than 60 years, hypertension, and diabetes mellitus have been identified as the major risk factors for severe cases of COVID-19. The knowledge about COVID-19’s immunopathogenesis has been increasing rapidly. Patients with hereditary angioedema (HAE) have been postulated to be at increased risk for COVID-19 infection due to inherent dysregulation of the plasma kallikrein-kinin system. However, no direct correlation was seen between hereditary angioedema and COVID-19. However, all this helped increase the awareness of the hereditary angioedema disease and this is expected to influence the market growth.

Based on Drug Class, the Hereditary Angioedema Market is segmented into C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, and Others. There are three types of hereditary angioedema, called types I, II, and III, which can be distinguished by their underlying causes and levels of a protein called C1 inhibitor in the blood. The different types have similar signs and symptoms.  

Based on Treatment Type, the Hereditary Angioedema Market is segmented into Prophylaxis and On-demand. On demand HAE, also known as acute treatment that is used to treat the symptoms of the HAE attack. The established treatment guidelines support the exploring of both preventive and acute therapy as part of the treatment plan. Patients with HAE are at high risk of attack on the airway due to which even after preventive medicine, it is important to seek on-demand treatment for many.

For a detailed analysis of the Route of Administration in the Hereditary Angioedema Market browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=15857

Based on Route of Administration, the Hereditary Angioedema Market is segmented into Intravenous, Subcutaneous, and Oral. C1-esterase inhibitor has an intravenous route of administration and since it is the most used medication for HEA. The first line of therapy for acute episodes of type I and II hereditary angioedema is replacing the missing protein with C1-INH concentrate, which halts the progression of the clinical manifestations within 20 minutes. This makes the intravenous route of administration the most used.

Request for Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=15857

Additionally, the report provides detailed initiatives that are being taken in the field of Hereditary Angioedema globally. The report provides a detailed analysis of regions including North America (US, Canada, Rest of North America), Europe (Germany, UK, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of Asia-Pacific), Rest of World. North America dominated the market in 2020, with XX% share.

CSL Behring, Takeda Pharmaceutical Company Limited, Sanofi, Pharming Healthcare Inc., BioCryst Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Ionis Pharmaceuticals, KalVista Pharmaceuticals Inc., Adverum Biotechnologies Inc., and Cipla Inc. are some of the major players operating in the Hereditary Angioedema market. Several M&As along with partnerships have been undertaken by these players to make treatment of Hereditary Angioedema as cost-effective and as widely available as possible.

Hereditary Angioedema Market Segmentation

Market Insight, by Drug Class

  • C1-esterase inhibitor
  • Bradykinin B2 receptor antagonist
  • Kallikrein inhibitor
  • Others

Market Insight, by Treatment Type

  • Prophylaxis
  • On-demand

Market Insight, by Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral

Market Insight, by Region

    • United States
    • Canada
    • Rest of North America
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Rest of Europe
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific

Top Company Profiles

  • CSL Behring
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Pharming Healthcare Inc.
  • BioCryst Pharmaceuticals Inc.
  • Attune Pharmaceuticals Inc.
  • Ionis Pharmaceuticals
  • KalVista Pharmaceuticals Inc.
  • Adverum Biotechnologies Inc.
  • Cipla Inc.

Leave A Comment

Select Language